Investors may be asking whether Moderna's current share price reflects its underlying worth, or if the market is mispricing ...

Moderna's full pipeline may fuel long-term growth.

European Medicines Agency approves Moderna's mRNA flu vaccine with strong efficacy in older adults. US FDA initially declines ...

In the latest trading session, Moderna (MRNA) closed at $49.20, marking a -1.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.11%. On the other hand, ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

They aren't just "pandemic stocks." ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...

After the Food and Drug Administration initially declined to review Moderna's mRNA flu vaccine candidate, the drugmaker said Wednesday that the FDA reversed its decision and will allow Moderna to move ...

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Pharma stocks took a fresh hit on Friday following a report in The Washington Post that the U.S. Food and Drug Administration reportedly plans to link COVID-19 vaccines with the deaths of 25 minors.